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All measured values were evaluated using the gamma index 
with dose difference/distance-to-agreement criteria of 3%/2 
mm (γ3%/2 mm) for the area receiving more than 10% isodose as 
compared with a static pattern. A γ passing rate > 90% was 
considered acceptable in this study. 
Results: For Group A, γ3%/2 mm was less than 90% for 
translational errors ≥ 3 mm in the LAT and VRT directions and 
≥ 2 mm in the LNG direction. For Group B, γ3%/2 mm was less 
than 90% for rotational errors ≥ 3° (Table 1). Table 2 
summarizes γ3%/2 mm for Group C. Translational errors of 2 mm 
and rotational errors of 2° always gave a γ3%/2 mm of less than 
90%. γ3%/2 mm was less than 90% for tilt and roll angles of 2°, 
even without translational errors. Even when translational 
errors were 1 mm, γ3%/2 mm was less than 90% for two patterns 
with rotational errors of 1°. By correcting the translational 
errors, γ3%/2 mm was more than 90% for tilt and roll angles of 
1°. Note that correction of the translational errors degraded 
γ3%/2 mm for the pattern with a tilt angle of 1° and roll angle of 
-1° and with a tile angle of 2° and roll angle of -2°. 
 
Conclusions: This study have demonstrated that rotational 
errors ≥ 3° in either angle or ≥ 1° in multiple angles most 
likely gave a γ3%/2 mm of less than 90%, even with translational 
errors < 2 mm; therefore, it is preferable to correct 
rotational errors < 2° in each angle for spine SRS under 
correction of translational errors.  
   
 
Symposium with Proffered Papers: Future directions for 
HPV negative head and neck cancer  
 
 
SP-0532   
Molecular imaging of proliferation and hypoxia 
J.H. Kaanders1, B.A. Hoeben1, J. Bussink1, W.J. Oyen2 
1Radboud University Medical Center, Radiation Oncology, 
Nijmegen, The Netherlands  
2Radboud Unicersity Medical Center, Medical Imaging, 
Nijmegen, The Netherlands  
 
HPV-status has been recognized as the strongest prognostic 
indicator for treatment outcome of oropharynx cancer 
overpowering clinical and other biological tumor 
characteristics. Nevertheless, the latter remain of value for 
selection of subgroups within the HPV-negative and HPV-
positive entities that qualify for treatment intensification or 
de-intensification, respectively. Among the clinical factors 
are smoking habits and T- and N-stage. Classical radio- and 
chemotherapy resistance mechanisms include DNA-repair 
capacity, tumor repopulation and hypoxia, for which various 
biomarkers have been identified. To improve the outcome of 
HPV-negative patients the challenge is to identify the pivotal 
resistance mechanisms and apposite treatments to 
counteract them. There will not be a “one-size-fits-all” 
solution and customized treatment additions and/or 
adaptations will be essential, necessitating selection tools. 
For a biomarker assay to be successful for wide clinical 
application it should preferably be non-invasive, fast, not too 
complex, and suited for repetitive assessments. PET-scanning 
meets these criteria although specific tracer availability can 
be a limitation. The current status and future directions of 
PET-scanning with proliferation- and hypoxia-specific tracers 
for outcome prediction and early response assessment will be 
discussed. 
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HPV negative head and neck cancer remains a challenging 
disease with a poor prognosis for many patients, especially 
those with locally advanced disease stage. 
Future developments are likely to focus on a number of 
areas. 
Techniques to identify and target patients with radioresistant 
disease are required. Current clinical trials in this area are 
testing radiation dose escalation to overcome 
radioresistance. Advances in functional imaging have allowed 
the detection of sub-volumes of radioresistant tumour tissue 
due to hypoxia, proliferation or other processes. Dose 
painting techniques are in development to attempt to deliver 
increased radiatin dose to these areas. 
In parallel the development of combinations of radiation with 
chemotherapy and novel agents are underway. The ability of 
agents to overcome the processes leading to radioresistance 
such as hypoxia, DNA damage repair and other processes will 
be discussed.  
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Purpose/Objective: In head and neck squamous cell 
carcinoma (HNSCC), the overall treatment time of radiation 
(OTT) is significantly associated with locoregional control 
(LRC), which is consistent with rapid repopulation of cancer 
clonogens during radiotherapy. However, the importance of 
